Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Generic EpiPen Hits CVS Shelves at Just Over $100 for Two-Pack



The epinephrine auto-injector is a generic version of the lesser-known Adrenaclick, and will be sold for $109.99 for a two-pack.

Share this!

January 16, 2017 | by Sarah Hand, M.Sc.

US pharmacy chain CVS has begun selling a generic version of Mylan’s EpiPen for about one sixth the price of the branded medicine. The epinephrine auto-injector is a generic version of the lesser-known Adrenaclick, and will be sold for $109.99 for a two-pack.

Mylan, makers of the EpiPen, have faced increased scrutiny over their pricing practices in recent years. Currently, a two pack of their device costs $600 – nearly six times the price of the generic.

According to CVS, they are offering the generic medical device at almost 50 percent of its original cost. The lower price will be available at all 9,600 retail locations of the pharmacy chain, including those located inside Target stores.

“We’re encouraged to see national efforts to make epinephrine auto-injectors more affordable and more available to Americans across the country,” said Dr. Cary Sennett, President and CEO of the Asthma and Allergy Foundation of America. “Partnerships that increase access to vital medications are key in helping those suffering from life-threatening allergies.”

The epinephrine auto injectors are used to treat anaphylaxis in patients with severe allergies. Since the drug expires after a year, patients must refill their prescriptions on an annual basis. The price increases have pushed some patients to hold onto their unused, expired EpiPens instead of buying new ones.

With a near-100 percent market share, the price of the EpiPen has increased over 500 percent since 2007. In September of last year, Mylan’s CEO Heather Bresch faced a Congressional panel on drug pricing where she defending the price increases by citing improvements made to the medical device’s design.

In December, Mylan launched its own generic version of the EpiPen, priced at 50 percent less than the original branded version. The company also expanded financial assistance options for patients who qualify.

Keywords: Generic, EpiPen, Drug Pricing


Share this with your colleagues!

Kite Pharma Secures FDA Approval for CAR-T Immunotherapy

October 20, 2017 - Kite Pharma’s Yescarta (axicabtagene ciloleucel) has become the second CAR-T immunotherapy to be approved in the US, with an indication in treating adult patients with relapsed or refractory large B-cell lymphoma.

Featured In: Biotech News

Fallopian Tubes Found to be Site of Origin for Most Ovarian Cancers

October 20, 2017 - This year, over 22,000 women will be diagnosed with ovarian cancer but a new study conducted by researchers at Perlmutter Cancer Center at NYU Langone Health suggests that most of these malignancies begin in another part of the reproductive system: the fallopian tubes.

Featured In: Life Science News

Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Brexit – Separating Fact from Fiction

Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond

Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms

Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution

Copyright © 2016-2017 Honeycomb Worldwide Inc.